Miranova (Ethinylestradiol, Levonorgestrel)

Ethinyloestradiol provides estrogenic activity that stabilises the uterine lining, while levonorgestrel, a progestogen, suppresses the mid‑cycle luteinising hormone surge, thereby inhibiting ovulation. Together they thicken cervical mucus and produce endometrial changes that reduce the likelihood of implantation.

The dosing regimen for Miranova is determined by the prescribing healthcare professional. Typically, the product is taken as one tablet daily at the same time each day, but the exact schedule and any missed‑dose instructions are provided by the prescriber.

Miranova is not intended for use during pregnancy; it is a contraceptive meant to prevent pregnancy. If pregnancy occurs, the product should be discontinued. Limited data are available for breastfeeding, and clinicians usually weigh the benefits against potential risks before prescribing to nursing mothers.

To order Miranova, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Miranova contains the standard dose combination of ethinyloestradiol and levonorgestrel, which is comparable to many other COC products on the market. Its efficacy, safety profile and side‑effect spectrum are similar to other estrogen‑progestin pills, with differences mainly in tablet size, inactive ingredients and regional branding.

Miranova tablets should be stored at ambient temperature below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Miranova is taken orally, usually as one tablet each day, preferably at the same time each day. The tablets are swallowed whole with water and should be started on the first day of the menstrual cycle or as directed by a healthcare professional.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, and cardiovascular complications like stroke or myocardial infarction. Rarely, severe allergic reactions may occur. Patients should seek immediate medical attention if they experience symptoms such as sudden leg pain, shortness of breath, chest pain, or severe rash.

Miranova is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, known or suspected breast cancer, active liver disease, or those who are pregnant. It should also be avoided in smokers over 35 years of age and in individuals with known hypersensitivity to any component of the tablet.